Neurology
Latest news
636 articles · 20 / page
FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications
The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained b
Manual Therapy Combined with Exercise for Neck Pain: An Evidence-Based Clinical Update
Systematic review evidence suggests manual therapy with exercise moderately improves function and reduces pain in chronic neck pain compared with no treatment; benefits versus placebo are less clear, highlighting need for further trials and
Beyond the Lesion: Long-Term Cardiovascular, Neurologic, Psychiatric, and Endocrine Risks After Traumatic Spinal Cord Injury
A large retrospective cohort study shows traumatic spinal cord injury (TSCI) is associated with increased long-term cardiovascular, neurologic, psychiatric, and endocrine morbidity and higher mortality, even in previously healthy adults.
Prehospital Postintubation Hypotension Strongly Linked to 30‑Day Mortality After Severe Traumatic Brain Injury — Especially in Isolated TBI
A multicenter cohort study of 555 patients with severe TBI who underwent prehospital rapid sequence induction found postintubation hypotension (SBP
Stage-specific Tau-PET Dynamics in Biological Alzheimer’s Disease: Implications for Trial Design and Outcome Selection
Longitudinal tau-PET accumulation follows distinct regional patterns across biological AD stages; aligning trial inclusion and outcome ROIs to baseline tau stage can substantially reduce sample sizes and improve power for disease-modifying
Your Nose Knows: How Smell Loss Signals More Than a Cold — Links to 139 Diseases and What to Do About It
A large prospective study links smell disturbances to at least 139 conditions. Olfactory loss can be an early sign of neurological, ENT, metabolic, or systemic disease — and a practical, underused screening tool clinicians can adopt.
Connectivity as a Universal Predictor of Tau Progression in Atypical Alzheimer’s Disease: A Multicentre Evidence Synthesis
Functional connectivity reliably predicts spatial and temporal tau propagation patterns across atypical Alzheimer’s disease variants, underpinning personalized approaches to diagnosis and therapy.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, p
Lower-than-Expected Hemorrhage Risk From Unruptured Brain AVMs: MARS Clarifies Natural History and Key Predictors
The MARS multicenter cohort (n=3030) found a lower annual intracranial hemorrhage risk (1.40%/yr) for unruptured brain AVMs than commonly cited. Older age, associated arterial aneurysms, and cerebellar/deep supratentorial location increased
Bridging IV Alteplase Before EVT Modestly Raises Intracranial Hemorrhage Risk — But Net Clinical Impact Is Complex
An IPD meta-analysis of six randomized trials (2313 patients) found IV alteplase before EVT modestly increased intracranial hemorrhage—particularly parenchymal hematoma—yet ICH risk must be balanced against IVT-associated improvements in re
Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
急性虚血性脳卒中における補助的静注アルガトロバンまたはエプチフィバチド投与：MOST無作為化臨床試験によるエビデンス
Recent multi-site randomized evidence demonstrates that adding intravenous argatroban or eptifibatide to standard thrombolysis within 3 hours of stroke onset does not improve functional recovery and is associated with increased mortality, i
White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances
This review synthesizes recent large-scale multi-cohort studies revealing white matter microstructural abnormalities—especially free water increases—in limbic tracts as critical markers of cognitive decline in aging and Alzheimer’s disease,
Paracetamol Lowers Cerebral Temperature in Febrile Brain‑Injured Patients — NEUROTHERM RCT Shows a Modest, Clinically Relevant Effect
In the NEUROTHERM randomized pharmacodynamic trial, a single IV dose of paracetamol reduced intracerebral temperature by a mean 0.6°C in febrile brain‑injured patients and kept temperatures
Free Water Collapse in Limbic White Matter Predicts Memory Decline in Aging and Alzheimer Disease
A large multisite analysis (n=4,467) finds white matter free water (FW), especially in limbic tracts (cingulum, fornix), strongly associates with cross-sectional cognition and longitudinal decline; FW interacts with amyloid, APOE ε4, and gr
Giving Thrombolysis Late — Before Transfer for Thrombectomy — May Improve Outcomes in AIS-LVO: Evidence from a 20-Center French Cohort
A multicenter retrospective cohort found that IV thrombolysis started beyond 4.5 hours and before interhospital transfer for EVT was associated with higher rates of spontaneous recanalization during transfer and better 3‑month functional ou
Paracetamol Lowers Cerebral Temperature Modestly but Meaningfully in Febrile Brain‑Injured Patients: Results of the NEUROTHERM Randomized Pharmacodynamic Trial
In a double‑blind RCT of 99 febrile brain‑injured patients with intracerebral thermal probes, a single IV dose of paracetamol reduced mean cerebral temperature by 0.6°C versus placebo and kept cerebral temperature
Neurologic Complications on VA‑ECMO Are Linked to Higher 6‑Month Mortality: Insights from a Binational Prospective Cohort
A prospective multicenter cohort of 704 adults on venoarterial ECMO found neurologic complications in 12% and that these events were associated with a 17% absolute increase in death or new disability at 6 months, driven mainly by higher mor
Eflornithine Plus Lomustine Extends Progression-Free and Overall Survival in Recurrent IDH‑Mutant Grade 3 Astrocytoma — Results from STELLAR Phase III
The STELLAR phase III trial found that eflornithine added to lomustine doubled PFS and significantly improved OS in patients with recurrent IDH‑mutant grade 3 astrocytoma after radiotherapy and temozolomide, with increased but manageable my
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding
Browse by specialty
Open language-specific specialty feeds and department pages.